From FDA decisions to key trial data, we've collected the most crucial headlines in cardiology from the last 3 months: catch up on what you missed with our Q3 2025 recap! Read now: www.hcplive.com/view...

New data from the LUCENT-3 open-label extension study establish mirikizumab (Omvoh) as the first and only IL-23p19 to help patients with moderately to severely active ulcerative colitis achieve sustained, long-term outcomes through 4 years. Read more: www.hcplive.com/view...

In a new study, secukinumab and ixekizumab had similar clinical efficacy in treating moderate-to-severe #psoriasis, but secukinumab was shown to offer superior psychological benefits. View here: www.hcplive.com/view...#psoriasis,

The FDA has approved donidalorsen (Dawnzera)—the first RNA-targeted therapy for hereditary angioedema (HAE). In an interview with Dr. William Lumry, he discusses how targeting prekallikrein opens a new path in HAE prevention. www.hcplive.com/view...

We spoke with Vimal H. Prajapati, MD, from @University of Calgary about the new FDA approval of guselkumab for pediatric psoriasis and psoriatic arthritis. Learn more about how the new approval's impact in the field now: www.hcplive.com/view/bridgin...

Come catch up on some of the most important #cardiology news with our Month in Review! From FDA approvals to professional insights, we've collected some unmissable headlines from September 2025. Read now: www.hcplive.com/view...

Today, the FDA approved roflumilast (Zoryve) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2-5 years of age, marking the 6th FDA approval for the PDE4 inhibitor’s portfolio in just over 3 years. Learn more: www.hcplive.com/view...

NEW: In a phase 2 proof-of-concept trial, treatment with topical bimiralisib gel 2% has achieved high rates of #ActinicKeratosis lesion clearance and has been well tolerated in patients with this condition. View here:

New research has shown that over 99% of patients who experience heart attacks, strokes, and heart failures had cardiovascular risk factors present prior, overturning a common misconception. Read now:

HCPLive has provided a review highlighting some of the most notable news coverage from the months of July, August, and September in #dermatology. View:

Hypertonic saline nasal irrigation reduces symptoms & antihistamine use in #AllergicRhinitis—but shows no significant edge over isotonic saline. #Allergy

Have you seen the latest #SkinofColorSavvy podcast? If not, check out this informative discussion between 4 experts in the field of dermatology. View:www.hcplive.com/view...#SkinofColorSavvy

Q3 Sleep Medicine Recap: • PAP therapy lowers BP & A1c in OSA, reducing CV risk. • Irregular or long sleep duration linked to ↑ mortality & CV events. • Tirzepatide shows promise for OSA. Read more here:

KDIGO recently released its 2025 Clinical Practice Guideline for the Management of IgAN and IgAV. For further insight into the document and its clinical implications, we spoke with Jonathan Barratt, MD, PhD:

Psychiatry Q3 2025 Recap: From FDA updates on acetaminophen & leucovorin to Fast Track & Breakthrough Therapy designations (NRX-100, TSND-201) + new phase 2 data in #MDD, #GAD & #PPD — explore the latest in mental health treatments.

In the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, met with Bob Vigersky, MD, chief medical officer at Medtronic Diabetes, to discuss recent advancements in diabetes care and glucose monitoring. Watch now: www.hcplive.com/view/diabete...

Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields. Check out the FDA approval highlights from the last quarter now:

Are you caught up on September's biggest headlines in #dermatology news?🤔 If you need a refresher, we've got you covered. Check out our summary of 11 headlines in the dermatology research space you might have missed. 🔗View here:

Hear from Jonathan Barratt, MD, PhD, about the evolving diagnostic and therapeutic landscape of IgAN and key recommendations from the new KDIGO guidelines. Check out the Q&A here:

Top Allergy Advances in Q3 2025: • Donidalorsen & Sebetralstat approved for #HAE • Cephalexin safe for penicillin-allergic patients • Cat & birch allergy blockers shine in phase 3 • CBT + intranasal epinephrine enhance patient care Full recap:

On the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, met with Bob Vigersky, MD, chief medical officer of Medtronic Diabetes, to discuss the company's latest advancements in the field. Watch now: www.hcplive.com/view/diabete...

We spoke to Julie Kimura, MD, Chief of Pediatric Rheumatology at Hackensack University Medical Center, and Professor of Pediatrics at the Hackensack Meridian School of Medicine, to learn more about transitioning care between childhood and adulthood arthritis. Watch now:

At #EADV2025, HCPLive spoke to Mona Shahriari, MD, associate clinical professor of dermatology at @Yale University and host of #TheMedicalSisterhood podcast, about which data released were among the most significant in #dermatology.

New study finds transthyretin cardiac amyloidosis (ATTR-CA) is a major, underdiagnosed cause of heart failure in older Black adults, with 17% of men ≥ 75 years affected. #HeartFailure #Cardiology

On the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the results of the STEP-UP trial, which showed the superior efficacy and safety of semaglutide 7.2 in obesity. Watch now: www.hcplive.com/view/diabete...

On the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking results from the ATTAIN-1 and STEP-UP trials. Watch now:

A new single center found that pain reductions in people with #fibromyalgia favored the placebo group over cannabidiol, although differences were not clinically meaningful. Read more: www.hcplive.com/view...

Hear from Kyle Staller, MD, MPH, Mass General, about new American Gastroenterologic Association guidelines on the diagnosis and management of gastroparesis. Watch now:

Meta-analysis shows CBT-I is highly effective for #insomnia in patients with chronic diseases; 54% achieved remission, improving #sleep across cancer, pain & CVD. www.hcplive.com/view...#insomnia#sleep#ChronicDisease

In a new Savvy Conversations episode of the #SkinofColorSavvy podcast 🎙️ Drs. Iltefat Hamzavi and Tasneem F. Mohammad, of @HenryFordHealth, touch on the complexities of managing #vitiligo across diverse patient populations. 🔗View:

CeleCor Therapeutics has announced positive topline results from their phase 3 CeleBrate trial, investigating zalunfiban's efficacy in treating ST-segment elevation myocardial infarction. Read more:

Findings from an analysis of STROKE-CARD Registry data shed light on psychosocial consequences associated with post-stroke dysphagia, including increased dependency in daily living and a greater risk of being unable to return to work. Learn more: www.hcplive.com/view...

New AKINESIS data: Kidney biomarker IGFBP-7 predicts 1-year mortality & #heartfailure readmission in acute heart failure, outperforming other tubular injury markers.

We spoke with Sonalika Khachikian, MD, an endocrinologist at Monument Health, to discuss a surprising gap in education around thyroid eye disease - one shared between patients and clinicians. Watch now:

Hear from Brendon Neuen, MBBS, about findings from his recent systematic review and meta-analysis of pooled phase 2 and phase 3 trial data assessing treatment effects of existing and novel IgA nephropathy therapies on proteinuria and eGFR slope. Watch now:

Global study of 30,000+ adults links #AtopicEczema to greater rates of suicidal ideation, depression, anxiety & sleep disorders. Findings highlight the need to address the hidden psychological burden. #EADV2025

New data reveals ritlecitinib's long-term efficacy for #AlopeciaAreata, showing sustained hair regrowth in 30% of patients after 3 years. Check out our interview with Brett King, MD, of @Yale, from #EADV2025: www.hcplive.com/view/long-te...

ICYMI: On Monday, Corstasis Therapeutics announced that the FDA has approved bumetanide nasal spray for the treatment of edema in heart, liver, and kidney diseases. Read more: www.hcplive.com/view...

ICYMI: Data from the SURPASS-PEDS trial have indicated the superiority of tirzepatide to placebo in treating adolescent type 2 diabetes. Read more:

ICYMI: KDIGO has released its 2025 Clinical Practice Guideline for the Management of IgAN and IgAV, providing comprehensive, evidence-based recommendations for clinicians managing these kidney diseases. Learn more: www.hcplive.com/view...

Based on an investigation of hypothetical economic situations, the introduction of lonapegsomatropin as a treatment for growth hormone disorder into the formulatory of a US health program could potentially reduce its total cost. Read more:

The American Gastroenterological Association has released its gastroparesis clinical practice guideline, offering 12 conditional recommendations for the diagnosis and management of the complex gastric motility disorder. Learn more: www.hcplive.com/view...

Phase 4 #MACROTrial confirms #EndoscopicSinusSurgery improves outcomes in chronic rhinosinusitis, while long-term #clarithromycin offers no significant benefit. #ENT #CRS

New at #EADV: Patients with psoriasis are at a significantly higher risk of developing age-related macular degeneration, according to a recent study. Read more: www.hcplive.com/view...

New data from the SURPASS-PEDS phase 3 trial shows the superiority of tirzepatide to placebo in treating type 2 diabetes in adolescent patients. Tirzepatide saw improvements in A1C and body mass index over a 30-week trial and 52-week extension. Read more: www.hcplive.com/view...

Yukiko Kimura, MD, highlighted some of her ongoing research tackling high priority questions in pediatric #arthritis. Watch now: www.hcplive.com/view...

Phase 4 #MACROTrial confirms endoscopic sinus surgery improves symptoms in #ChronicRhinosinusitis. Long-term low-dose clarithromycin showed no benefit. #ENT #SinusHealth www.hcplive.com/view...

The recent Mighty-Heart trial has found no benefit to health status or hospital readmissions using mobile integrated health versus transitions of care coordinators for postacute patients with heart failure. Read more: www.hcplive.com/view...

Listen to an audio recap of the top 5 stories in healthcare news from the week of 9/5-9/14 now, with new updates in MASH and FSGS.

PRT120 peanut oral immunotherapy wins #EAACI Prize for 3-year post-treatment remission. Children can safely eat peanuts without daily dosing, highlighting remission as the key treatment goal. #PeanutAllergy #OIT www.hcplive.com/view...#EAACI